New Delhi, Oct. 9 -- A major new study presented at United European Gastroenterology (UEG) Week 2025 reveals that both sugar-sweetened beverages (SSBs) and low- or non-sugar-sweetened beverages (LNSSBs) are significantly associated with an increased risk of metabolic dysfunction-associated steatotic liver disease (MASLD).

The research followed 123,788 UK Biobank participants without pre-existing liver disease, using repeated 24-hour dietary questionnaires to assess beverage consumption. The study tracked the development of MASLD, liver fat accumulation, and liver-related mortality over a median 10.3-year follow-up.

Participants consuming over 250g per day of LNSSBs or SSBs were found to have a 60% (HR: 1.599) and 50% (HR: 1.469) higher ...